Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

HABA LaboratoriesInc Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

HABA LaboratoriesInc şirketinin toplam hissedar öz sermayesi ¥8.3B ve toplam borcu ¥2.1B olup, bu da borç-öz sermaye oranını 25.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥12.1B ve ¥3.7B dir. HABA LaboratoriesInc 'in FAVÖK'ü ¥66.0M faiz karşılama oranı 6 dur. Şirketin ¥3.7B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

25.5%

Borç/özkaynak oranı

JP¥2.13b

Borç

Faiz karşılama oranı	6x
Nakit	JP¥3.73b
Eşitlik	JP¥8.33b
Toplam yükümlülükler	JP¥3.72b
Toplam varlıklar	JP¥12.06b

Son finansal sağlık güncellemeleri

These 4 Measures Indicate That HABA LaboratoriesInc (TYO:4925) Is Using Debt Reasonably Well

Feb 19

Recent updates

What Type Of Returns Would HABA LaboratoriesInc's(TYO:4925) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

Mar 09

These 4 Measures Indicate That HABA LaboratoriesInc (TYO:4925) Is Using Debt Reasonably Well

Feb 19

Should You Be Impressed By HABA LaboratoriesInc's (TYO:4925) Returns on Capital?

Feb 01

Is HABA Laboratories,Inc. (TYO:4925) A Smart Choice For Dividend Investors?

Jan 13

HABA Laboratories,Inc.'s (TYO:4925) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

Dec 25

What Kind Of Investors Own Most Of HABA Laboratories,Inc. (TYO:4925)?

Dec 07

A Look At HABA LaboratoriesInc's (TYO:4925) Share Price Returns

Nov 19

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4925 'nin kısa vadeli varlıkları ( ¥8.7B ) kısa vadeli yükümlülüklerini ( ¥2.7B ) aşıyor.

Uzun Vadeli Yükümlülükler: 4925 şirketinin kısa vadeli varlıkları ( ¥8.7B ) uzun vadeli yükümlülüklerini ( ¥989.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4925 şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: 4925 şirketinin borç/öz sermaye oranı son 5 yılda 15.6% seviyesinden 25.5% seviyesine yükseldi.

Borç Kapsamı: 4925 'nin işletme nakit akışı negatif olduğundan borçlar iyi karşılanamıyor.

Faiz Kapsamı: 4925 'in borcuna ilişkin faiz ödemeleri EBIT ( 6 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

HABA LaboratoriesInc Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Haba Laboratories Ordinary Shares to Be Deleted from Other OTC

These 4 Measures Indicate That HABA LaboratoriesInc (TYO:4925) Is Using Debt Reasonably Well

Recent updates

HABA Laboratories,Inc. to Report Q2, 2025 Results on Nov 13, 2024

New major risk - Financial data availability

Full year 2024 earnings released: JP¥560 loss per share (vs JP¥187 loss in FY 2023)

HABA Laboratories,Inc. to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings released: JP¥560 loss per share (vs JP¥187 loss in FY 2023)

HABA Laboratories,Inc., Annual General Meeting, Jun 23, 2024

HABA Laboratories,Inc. to Report Fiscal Year 2024 Results on May 10, 2024

Upcoming dividend of JP¥40.00 per share

Third quarter 2024 earnings released: JP¥150 loss per share (vs JP¥153 loss in 3Q 2023)

HABA Laboratories,Inc. to Report Q3, 2024 Results on Feb 09, 2024

Second quarter 2024 earnings released: JP¥34.38 loss per share (vs JP¥23.80 loss in 2Q 2023)

HABA Laboratories,Inc. to Report Q2, 2024 Results on Nov 10, 2023

First quarter 2024 earnings released: JP¥56.86 loss per share (vs JP¥37.02 loss in 1Q 2023)

HABA Laboratories,Inc. to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings released: JP¥187 loss per share (vs JP¥71.14 loss in FY 2022)

Full year 2023 earnings released: JP¥187 loss per share (vs JP¥71.14 loss in FY 2022)

HABA Laboratories,Inc., Annual General Meeting, Jun 18, 2023

Upcoming dividend of JP¥40.00 per share at 1.7% yield

Third quarter 2023 earnings released: JP¥153 loss per share (vs JP¥17.19 loss in 3Q 2022)

HABA Laboratories,Inc. to Report Q3, 2023 Results on Feb 10, 2023

Second quarter 2023 earnings released: JP¥23.80 loss per share (vs JP¥49.98 loss in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: JP¥23.80 loss per share (vs JP¥49.98 loss in 2Q 2022)

HABA Laboratories,Inc. to Report Q2, 2023 Results on Nov 11, 2022

First quarter 2023 earnings released: JP¥37.02 loss per share (vs JP¥72.72 loss in 1Q 2022)

Haba Laboratories Ordinary Shares to Be Deleted from Other OTC

Full year 2022 earnings released: JP¥71.14 loss per share (vs JP¥57.12 profit in FY 2021)

HABA Laboratories,Inc. to Report Q1, 2023 Results on Aug 12, 2022

Full year 2022 earnings released: JP¥71.14 loss per share (vs JP¥57.12 profit in FY 2021)

HABA Laboratories,Inc., Annual General Meeting, Jun 19, 2022

Less than half of directors are independent

HABA Laboratories,Inc. to Report Fiscal Year 2022 Results on May 11, 2022

Upcoming dividend of JP¥40.00 per share

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2022 earnings released: JP¥49.98 loss per share (vs JP¥1.59 loss in 2Q 2021)

First quarter 2022 earnings released: JP¥72.72 loss per share (vs JP¥51.57 loss in 1Q 2021)

Full year 2021 earnings released: EPS JP¥57.12 (vs JP¥339 in FY 2020)

Full year 2021 earnings released: EPS JP¥57.12 (vs JP¥339 in FY 2020)

Upcoming dividend of JP¥40.00 per share

What Type Of Returns Would HABA LaboratoriesInc's(TYO:4925) Shareholders Have Earned If They Purchased Their SharesThree Years Ago?

New 90-day high: JP¥4,515

These 4 Measures Indicate That HABA LaboratoriesInc (TYO:4925) Is Using Debt Reasonably Well

Third quarter 2021 earnings released: EPS JP¥30.15 (vs JP¥42.27 in 3Q 2020)

New 90-day high: JP¥4,350

Should You Be Impressed By HABA LaboratoriesInc's (TYO:4925) Returns on Capital?

Is HABA Laboratories,Inc. (TYO:4925) A Smart Choice For Dividend Investors?

HABA Laboratories,Inc. to Report Q3, 2021 Results on Feb 12, 2021

HABA Laboratories,Inc.'s (TYO:4925) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong?

What Kind Of Investors Own Most Of HABA Laboratories,Inc. (TYO:4925)?

A Look At HABA LaboratoriesInc's (TYO:4925) Share Price Returns

Second quarter 2021 earnings released: JP¥1.59 loss per share

New 90-day low: JP¥4,055

HABA Laboratories,Inc. to Report Q2, 2021 Results on Nov 11, 2020

First quarter earnings released

New 90-day low - JP¥4,060

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Sağlıklı şirketleri keşfedin